Patient P-03288
Therapy response
Favorable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
8%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S15
- Day 81 CR-01 recommended — Clinician Review CR-01
- Day 82 Patient accepted — Started CR-01 in the companion
- Day 87 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+4
- Treatment adherence+4
- Nutritional resilience+2
What helped?
- Clinician Review CR-01Day 81Result: deterioration detected before clinical escalation
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log7.5/10
stable · -0.2 vs previous 14 d
Stress level
Daily log2.7/10
stable · +0.1 vs previous 14 d
Pessimism score
Daily log2.1/10
worsening · +0.2 vs previous 14 d
Sleep quality
Wearable55/100
worsening · -2.7 vs previous 14 d
Libido
Daily log6.4/10
stable · -0.0 vs previous 14 d
HRV
Wearable54.7 ms
stable · -0.2 vs previous 14 d
Toxicity
Blood5.5/100
improving · -3.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 101 from the failing basin, 14 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.1 next day on high-intake days · n 19
Would not help
- Keep caffeine lowGI +4.9 next day on high-intake days · n 23
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Caffeine+4.9detractor · 95%
- Protein-4.1supporter · 95%
- Histamine load-2no signal · 30%
- Alcohol-0.9no signal · 17%
- Dietary fat load-0.6no signal · 15%
- Lactose+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.3 · butyrate capacity 45/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 6.9 h
- Steps
- 5,425
- Resting HR
- 71 bpm
Daily log: GI score 11, nutritional resilience 68, adherence 96.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03140 | 49% | S20 | AD-05 | improved | 79 |
| P-03187 | 35% | S12 | AD-05 | no change | 80 |
| P-03482 | 27% | S05 | AD-05 | no change | 67 |
| P-03105 | 26% | S12 | AD-05 | no change | 60 |
| P-03208 | 28% | S02 | BR-03 | improved | 57 |
| P-03001 | 45% | S04 | CR-01 | improved | 87 |
| P-03431 | 48% | S05 | DT-01 | improved | 88 |
| P-03353 | 41% | S06 | DT-01 | no change | 83 |
| P-03449 | 32% | S14 | DT-01 | improved | 79 |
| P-03473 | 28% | S07 | DT-01 | improved | 70 |
| P-03268 | 26% | S15 | DT-01 | improved | 56 |
| P-03143 | 25% | S11 | DT-01 | improved | 49 |